It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Compared to adults, children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have predominantly mild or asymptomatic infections, but the underlying immunological differences remain unclear. Here, we describe clinical features, virology, longitudinal cellular, and cytokine immune profile, SARS-CoV-2-specific serology and salivary antibody responses in a family of two parents with PCR-confirmed symptomatic SARS-CoV-2 infection and their three children, who tested repeatedly SARS-CoV-2 PCR negative. Cellular immune profiles and cytokine responses of all children are similar to their parents at all timepoints. All family members have salivary anti-SARS-CoV-2 antibodies detected, predominantly IgA, that coincide with symptom resolution in 3 of 4 symptomatic members. Plasma from both parents and one child have IgG antibody against the S1 protein and virus-neutralizing activity detected. Using a systems serology approach, we demonstrate higher levels of SARS-CoV-2-specific antibody features of these family members compared to healthy controls. These data indicate that children can mount an immune response to SARS-CoV-2 without virological confirmation of infection, raising the possibility that immunity in children can prevent the establishment of SARS-CoV-2 infection. Relying on routine virological and serological testing may not identify exposed children, with implications for epidemiological and clinical studies across the life-span.
Children with SARS-CoV-2 infection are more likely to have mild symptoms and may be asymptomatic, but underlying reasons remain unclear. Here, the authors show cellular, cytokine and antibody response to SARS-CoV-2 infection in three children who repeatedly tested negative for the virus by PCR, despite high exposure in the household.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


















1 The University of Melbourne, Department of Paediatrics, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Infection and Immunity, Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X); The Royal Children’s Hospital, Department of General Medicine, Melbourne, Australia (GRID:grid.416107.5) (ISNI:0000 0004 0614 0346)
2 The University of Melbourne, Department of Paediatrics, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Infection and Immunity, Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X)
3 The University of Melbourne, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
4 Infection and Immunity, Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X)
5 The University of Melbourne, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Department of Hematopoiesis, Amsterdam, Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262)
6 University of Michigan, Department of Biomedical Engineering, MI, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
7 Launceston General Hospital, Department of Infectious Diseases, Launceston, Australia (GRID:grid.415834.f) (ISNI:0000 0004 0418 6690); University of Tasmania, School of Health Sciences and School of Medicine, Launceston, Australia (GRID:grid.1009.8) (ISNI:0000 0004 1936 826X); Monash University, Department of Immunology and Pathology, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); RMIT University, School of Health and Biomedical Science, Melbourne, Australia (GRID:grid.1017.7) (ISNI:0000 0001 2163 3550)
8 The University of Melbourne, Department of Paediatrics, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Infection and Immunity, Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X); Infectious Diseases Unit, Department of General Medicine, The Royal Children’s Hospital, Melbourne, Australia (GRID:grid.416107.5) (ISNI:0000 0004 0614 0346)
9 The University of Melbourne, Department of Paediatrics, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Infection and Immunity, Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X); Department of Gastroenterology, The Royal Children’s Hospital, Melbourne, Australia (GRID:grid.416107.5) (ISNI:0000 0004 0614 0346)
10 The University of Melbourne, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia (GRID:grid.1008.9)